Journal of Clinical Endocrinology & Metabolism, Vol 72, 993-1000, Copyright © 1991 by Endocrine Society

ARTICLES

Variable tolerance of the developing follicle and corpus luteum to gonadotropin-releasing hormone antagonist-induced gonadotropin withdrawal in the human

JE Hall, N Bhatta, JM Adams, JE Rivier, WW Vale and WF Crowley Jr
Department of Medicine, Massachusetts General Hospital, Boston 02114.

To examine the differential sensitivity of the ovary to temporary withdrawal of gonadotropin support at different stages of folliculogenesis and corpus luteum function, GnRH antagonist blockade of gonadotropin secretion was examined in 17 studies using the Nal-Glu GnRH antagonist. A vehicle control, antagonist treatment, and follow-up cycle format was used in each study. A previously determined ED100 dose of the Nal-Glu GnRH antagonist (150 micrograms/kg) or vehicle was administered sc every 24 h for 3 consecutive days in the midfollicular phase (MFP), late follicular phase (LFP), and midluteal phase (MLP). In studies in the MFP (n = 7), the largest follicle was 11 +/- 2 mm (mean +/- SEM), and the mean estradiol (E2) level was 220 +/- 44 pmol/L on the first day of antagonist administration. Administration of the antagonist resulted in a 75 +/- 6% suppression of LH (P less than 0.005), no significant change in FSH, and suppression of E2 to the assay detection limit (P less than 0.05). Total cycle length was increased compared to that of the vehicle control cycle (37.3 +/- 1.3 vs. 26.3 +/- 1.1 days; (P less than 0.005) due to prolongation of follicular phase length (P less than 0.005) and reinitiation of folliculogenesis. In the LFP (n = 5), the largest follicle was 16 +/- 1 mm (P less than 0.05 vs. MFP), and the E2 level was 394 +/- 95 pmol/L (P less than 0.05 vs. MFP) on the first day of antagonist administration. Antagonist administration resulted in a 65 +/- 6% suppression of LH (P less than 0.05), a 47 +/- 11% decrease in FSH (P less than 0.05), and no significant change in E2. Total cycle length was prolonged (32.4 +/- 2.2 vs. 25.6 +/- 0.4 days; P less than 0.05) due to an increase in follicular phase length (P less than 0.02); however, the prolongation of the follicular phase was significantly less than that of the MFP (8.0 +/- 1.5 vs. 15.1 +/- 0.1 days; P less than 0.001), suggesting ovulation from the initial dominant follicle. In studies in the MLP (n = 5), LH, E2, and progesterone decreased to the assay detection limit after antagonist administration, while FSH decreased by 36 +/- 4% (P less than 0.05). Menstrual bleeding occurred within 24-48 h of the final Nal-Glu antagonist injection.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				F. H. Thomas, H. Wilson, A. Silvestri, and H. M. Fraser Thrombospondin-1 Expression Is Increased during Follicular Atresia in the Primate Ovary Endocrinology, January 1, 2008; 149(1): 185 - 192. [Abstract] [Full Text] [PDF]

				F. H. Thomas, E. E. Telfer, and H. M. Fraser Expression of Anti-Mullerian Hormone Protein during Early Follicular Development in the Primate Ovary in Vivo Is Influenced by Suppression of Gonadotropin Secretion and Inhibition of Vascular Endothelial Growth Factor Endocrinology, May 1, 2007; 148(5): 2273 - 2281. [Abstract] [Full Text] [PDF]

				N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]

				P D Taylor, S G Hillier, and H M Fraser Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary J. Endocrinol., October 1, 2004; 183(1): 1 - 17. [Abstract] [Full Text] [PDF]

				M.H. Mochtar and on behalf of The Dutch Ganirelix Study Group The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI Hum. Reprod., August 1, 2004; 19(8): 1713 - 1718. [Abstract] [Full Text] [PDF]

				S. B. Seminara, M. Beranova, L. M. B. Oliveira, K. A. Martin, W. F. Crowley Jr., and J. E. Hall Successful Use of Pulsatile Gonadotropin-Releasing Hormone (GnRH) for Ovulation Induction and Pregnancy in a Patient with GnRH Receptor Mutations J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 556 - 562. [Abstract] [Full Text]

				G. D. Niswender, J. L. Juengel, P. J. Silva, M. K. Rollyson, and E. W. McIntush Mechanisms Controlling the Function and Life Span of the Corpus Luteum Physiol Rev, January 1, 2000; 80(1): 1 - 29. [Abstract] [Full Text] [PDF]

				C. K. Welt, J. M. Adams, P. M. Sluss, and J. E. Hall Inhibin A and Inhibin B Responses to Gonadotropin Withdrawal Depends on Stage of Follicle Development J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2163 - 2169. [Abstract] [Full Text]

				I. Schipper, W. C. J. Hop, and B. C. J. M. Fauser The Follicle-Stimulating Hormone (FSH) Threshold/Window Concept Examined by Different Interventions with Exogenous FSH during the Follicular Phase of the Normal Menstrual Cycle: Duration, Rather Than Magnitude, of FSH Increase Affects Follicle Development J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1292 - 1298. [Abstract] [Full Text]

				R. Alvero, L. Kimzey, N. Sebring, J. Reynolds, M. Loughran, L. Nieman, and B. R. Olson Effects of Fasting on Neuroendocrine Function and Follicle Development in Lean Women J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 76 - 80. [Abstract] [Full Text]

				E. J. P. van Santbrink and B. C. J. M. Fauser Urinary Follicle-Stimulating Hormone for Normogonadotropic Clomiphene-Resistant Anovulatory Infertility: Prospective, Randomized Comparison between Low Dose Step-Up and Step-Down Dose Regimens J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3597 - 3602. [Abstract] [Full Text] [PDF]

				B. C. J. M. Fauser and A. M. van Heusden Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences Endocr. Rev., February 1, 1997; 18(1): 71 - 106. [Abstract] [Full Text]